Neopharm네오팜
092730 · KOSDAQ · ₩092730 · 네오팜
- Market cap
- ₩354B
- Enterprise value
- ₩332B
- P/E
- 9.4×
- P/B
- 1.8×
- Dividend yield
- 0.0%
- ROE
- 18.8%
- Net margin
- 25.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−15.0% from the high
₩15,590Today: ₩21,900 – ₩23,350₩26,000
Returns
- 1W−6.4%
- 1M−6.6%
- 3M+14.5%
- 6M+10.0%
- YTD+20.3%
- 1Y+25.1%
- Volume today
- 45,626
- 1.0× the 20-day average
- Traded today
- ₩1B
- Listed shares
- 16,027,989
- EPS (12 months)
- ₩2,353
- Earnings yield 10.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−5.4% on Oct 26, 2026.
- • Foreign investors sold a net ₩345M that day
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- MomentumWeak-6.2% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Neopharm stock overview
Neopharm (네오팜, KRX: 092730) is listed on KOSDAQ, in the Cosmetics sector. The company develops and sells skincare and cosmetics, with brands including Atopalm for sensitive skin, Real Barrier for skin barrier care, Dermavie for body moisturizing, TL'S with a clean beauty concept, and Zeroid for medical skincare. Its shares closed at ₩22,100 on Oct 26, 2026, down 5.35% on the day, giving it a market value of ₩354B.
Key facts
- Market cap
- ₩354B
- Sector
- Cosmetics
- Latest price change
- −5.35%
- As of
- Oct 26, 2026
- Main business
- The company develops and sells skincare and cosmetics, with brands including Atopalm for sensitive skin, Real Barrier for skin barrier care, Dermavie for body moisturizing, TL'S with a clean beauty concept, and Zeroid for medical skincare.
Quick answers about Neopharm
- What does Neopharm do?
- The company develops and sells skincare and cosmetics, with brands including Atopalm for sensitive skin, Real Barrier for skin barrier care, Dermavie for body moisturizing, TL'S with a clean beauty concept, and Zeroid for medical skincare. Its products are based on its proprietary MLE formulation technology and are sold to consumers through online platforms, shopping channels, retail and duty-free stores, hospitals, and distributors, with exports to overseas markets.
- What is the market cap of Neopharm?
- The market capitalisation of Neopharm was ₩354B at the close on Oct 26, 2026.
- Who are the largest shareholders of Neopharm?
- According to the latest official filings, the largest reported holders are It's Hanbul (42.34%, as of May 6, 2026); FILLIMITED (9.40%, as of Jun 8, 2026); National Pension Service (1.97%, as of Dec 31, 2025).
- When is the next earnings report from Neopharm?
- Korean companies rarely announce results dates in advance. Based on when Neopharm filed the same report in past years, its next 3q results is expected between Nov 10, 2026 and Nov 14, 2026.
- Does the National Pension Service own Neopharm?
- Yes. The National Pension Service held 1.97% of Neopharm shares as of Dec 31, 2025.
Company profile
The company develops and sells skincare and cosmetics, with brands including Atopalm for sensitive skin, Real Barrier for skin barrier care, Dermavie for body moisturizing, TL'S with a clean beauty concept, and Zeroid for medical skincare. Its products are based on its proprietary MLE formulation technology and are sold to consumers through online platforms, shopping channels, retail and duty-free stores, hospitals, and distributors, with exports to overseas markets.
Written by AI from the company's latest annual report.
- Korean name
- 네오팜
- Sector
- Cosmetics
- Themes
- K-beauty
- CEO
- 김양수
- Founded
- Jul 2000
- Listed
- Jan 2007
- Listed shares
- 16,027,989
- Fiscal year ends
- Month 12
- Website
- neopharm.co.kr
Similar companies
- APR278470 · ₩11T₩282,000−0.88%
- Amorepacific090430 · ₩7.4T₩125,700−2.41%
- LG H&H051900 · ₩3.9T₩257,500−2.28%
- Cosmax192820 · ₩3T₩268,000−1.65%
- Kolmar Korea161890 · ₩2.8T₩117,400−4.16%
- d'Alba Global483650 · ₩1.9T₩149,300−1.52%
- Amorepacific Holdings002790 · ₩1.8T₩23,950−2.44%
- Cosmecca Korea241710 · ₩1.1T₩102,200−2.01%
Recent filings
See all- Investor relations (IR) eventAug 24, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earningsAug 7, 2026
- 5%+ holding reportJun 8, 2026
- Quarterly report (Mar 2026)May 14, 2026
Titles in Korean until English translations are added.
Also known as: Neopharm / 네오팜 / 092730 / KRX:092730
Source: KRX statistical information